WOS

Permanent URI for this collectionhttps://hdl.handle.net/11443/932

Browse

Subject: search.filters.subject.Annexin A2

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Circulating annexin A2 as a biomarker in patients with pancreatic cancer
    (WOLTERS KLUWER MEDKNOW PUBLICATIONS, 2020-01-01) Karabulut, Mehmet; Afsar, Cigdem Usul; Serilmez, Murat; Karabulut, Senem
    Background: Pancreatic cancer (PC) is a highly lethal malignancy. There are only few predictive or prognostic markers for PC. This study was conducted to investigate the serum levels of annexin A2 (AnxA2) in patients with PC and its relationship with tumor progression and known prognostic parameters. Materials and Methods: Serum samples were obtained on the first admission before any treatment. Serum AnxA2 levels were determined using enzyme-linked immunosorbent assay. Age- and sex-matched healthy controls were included in the analysis. All statistical tests were carried out using two-sided test, and P <= 0.05 was considered statistically significant. Results: The median age at diagnosis was 59 years. The most common metastatic site was liver in 23 patients with metastasis (n = 19, 83\%). At the end of the observation period, thirty-two patients (97\%) were dead. Thirty-nine percent of 23 metastatic patients who received palliative chemotherapy (CTx) were CTx responsive. Median overall survival of the whole group was 41.3 +/- 8.3 weeks (95\% confidence interval = 25-58 weeks). The baseline serum AnxA2 levels were significantly higher in patients with PC than in the control group (P = 0.01). Serum AnxA2 levels were significantly higher in the patients with high erythrocyte sedimentation rate (P = 0.04). Conversely, serum AnxA2 concentration had no prognostic role on survival (P = 0.18). Conclusions: AnxA2 is identified as a novel secretory biomarker for PC, but it has no role as a prognostic or predictive marker.
  • No Thumbnail Available
    Item
    Serum Annexin A2 Levels in Patients with Colon Cancer in Comparison to Healthy Controls and in Relation to Tumor Pathology
    (INT SCIENTIFIC INFORMATION, INC, 2014-01-01) Gurluler, Ercument; Guner, Osman Serhat; Tumay, Latif Volkan; Kucukmetin, Nurten Turkel; Hizli, Banu; Zorluoglu, Abdullah
    Background: The deregulation and localization of the Annexins is consistently reported to have close relation to tumor cell malignancy, invasion, and metastasis as well as clinical progression of tumors. This study aimed to evaluate serum Annexin A2 (Anx A2) levels in patients with colon cancer in comparison to healthy controls and in relation to demographics and tumor pathology. Material/Methods: A total of 100 patients (mean (SD) age: 58 (5.8) years, 55.0\% females) with colon cancer and 70 controls (mean (SD) age: 59 (5.4) years, 50.0\% females) were included. Serum levels for Anx A2 were evaluated in relation to study group, demographics, and tumor pathology. Results: Serum levels for Anx A2 were significantly lower in patients with colon cancer than in controls (13.1 (4.5) vs. 22.8 (2.1) ng/mL, p<0.001) and significantly decreased with increase in tumor size (p=0.003), and at higher stages of TNM (p=0.004), tumor invasion (p=0.005), lymph node metastasis (p=0.003), and distant metastasis (p=0.005). Conclusions: Our findings indicate a significant decrease in Anx A2 expression in colon cancer patients compared to healthy controls and in parallel with tumor progression.